Clavi-Q-RE is a next-generation autologous cancer immunotherapy, designed by RGCC and offered through Neeli Genetics. It leverages your body’s own immune cells, trained and activated in the lab to specifically target cancer cells based on your unique molecular and genetic profile. This is cancer care personalised not just by your DNA but by your immune fingerprint.
Clavi-Q-RE is developed from your own immune cells. After a blood sample is collected, RGCC’s advanced labs isolate and train your natural killer (NK) cells and cytotoxic T-cells to recognize your specific tumor antigens. This immune cell “education” is guided by molecular profiling including your:
Once activated, your own immune cells are re-infused, and they seek out and destroy cancer cells with high precision and minimal collateral damage.
Clavi-Q-RE enhances your immune system’s innate intelligence by:
It is especially effective for patients who have failed standard chemotherapy or those with high levels of immune evasion or checkpoint suppression.
Autologous & Safe: By using your own cells, the immune system is retrained for battle rather than using the donors’ cells
Immune-Enhancing: Unlike chemotherapy, it builds your immune strength over time.
Part of an Integrative Cancer Protocol: Pairs well with RGCC Comprehensive Treatment profiling, Immune assessment, metabolic therapies, and targeted supplements for long-term disease control.
Start with a consultation to evaluate whether Clavi-Q-RE is suitable based on your cancer stage, treatment history, and immune profile.
Our RGCC-trained specialists assess your eligibility and walk you through the logistics, sample requirements, and expected benefits.
A blood sample is drawn and sent to RGCC’s certified lab for processing and cellular activation.
In 3–4 weeks, your personalized Clavi-Q-RE therapy is ready. It is administered under medical supervision at an authorized facility.
Clavi-Q-RE is designed for patients with most solid tumours and blood cancers, especially those who have not responded well to conventional treatments like chemotherapy or radiation. Eligibility is determined through a thorough consultation and immune profiling by RGCC-trained specialists.
Yes. Since Clavi-Q-RE uses your own immune cells (autologous therapy), the risk of rejection or adverse immune reaction is significantly minimised. It is a non-toxic alternative to conventional therapies, aimed at strengthening rather than suppressing your immune system.
The complete turnaround time is approximately 30 days, which includes blood sample collection, immune cell isolation and activation in the lab, quality control, and shipment to the authorised treatment facility.
Absolutely. Clavi-Q-RE can be used alongside other therapies such as kinase inhibitors, low-dose chemotherapy, angiogenesis blockers, or metabolic therapies. This integrative approach allows for a comprehensive, personalised cancer treatment plan.
Clavi-Q-RE stands out due to its precision and personalisation. Unlike off-the-shelf treatments, this therapy is tailored using your own immune cells and guided by your tumour’s genetic, molecular, and proteomic profile, making it one of the most targeted and individualised forms of immunotherapy in Hyderabad available today.
Offering personalized tests from RGCC, our mission is to improve treatment outcomes, enhance survival rates, and elevate overall quality of life for those affected by cancer.
© 2025 Neeli Genetics. All Rights Reserved.